OraSure Technologies, Inc. Appoints Vice President, Corporate Communications
July 23 2018 - 7:34AM
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care
diagnostics and specimen collection devices, today announced that
Jeanne Mell has been appointed as the Company’s new Vice President,
Corporate Communications. Ms. Mell will join OraSure on August 13,
2018.
Most recently, Ms. Mell served as Vice President
Marketing Communications at the University City Science Center in
Philadelphia, where she was responsible for corporate marketing,
program development, communications, public and media relations and
community engagement. Ms. Mell also launched Quorum, the Science
Center’s clubhouse for entrepreneurs, and the Science Center’s
Innovators Walk of Fame.
Immediately before joining the Science Center,
Ms. Mell was Senior Vice President, Communications for the Delaware
State Chamber of Commerce. Prior to joining the Chamber, Ms. Mell
had a career in journalism at The News Journal in Delaware, the
Associated Press in New York and Philadelphia, ABC News, Good
Morning America and Popular Photography Magazine. She started her
career at Inc. Magazine.
Ms. Mell is the immediate past chair of Campus
Philly and also served as Vice President of the Association of
University Research Parks.
Ms. Mell is a graduate of the University of
California, Santa Cruz.
“We are delighted to welcome Jeanne as the
Company’s new Vice President, Corporate Communications. Jeanne’s
extensive communications expertise in conjunction with her public
and media relations experience will play a key role in reinforcing
and augmenting OraSure’s corporate identity and thought leadership
within the global community,” said Stephen S. Tang, Ph.D.,
President and CEO of OraSure Technologies.
About OraSure
Technologies
OraSure Technologies is a leader in the
development, manufacture and distribution of point of care
diagnostic and collection devices and other technologies designed
to detect or diagnose critical medical conditions. Its
first-to-market, innovative products include rapid tests for the
detection of antibodies to HIV and HCV on the
OraQuick® platform, oral fluid sample collection,
stabilization and preparation products for molecular diagnostic
applications, and oral fluid laboratory tests for detecting various
drugs of abuse. OraSure's portfolio of products is sold
globally to various clinical laboratories, hospitals, clinics,
community-based organizations and other public health
organizations, research and academic institutions, distributors,
government agencies, physicians' offices, commercial and industrial
entities and consumers. The Company's products enable healthcare
providers to deliver critical information to patients, empowering
them to make decisions to improve and protect their health.
For more information on OraSure Technologies, please
visit www.orasure.com.
Company contact:
Roberto Cuca |
Shauna
White |
Chief Financial
Officer |
Corporate
Marketing Manager |
610-882-1820 |
484-353-1575 |
Investorinfo@orasure.com |
media@orasure.com |
www.orasure.com |
www.orasure.com |
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jul 2023 to Jul 2024